Neuroinflammation - Pipeline Review - H2 2013





Published: November 2013 | Pages: 45 | Format: PDF

 Summary 

 Global Markets Direct’s, 'Neuroinflammation - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Neuroinflammation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuroinflammation. Neuroinflammation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. 

 Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 

 Scope 

  •  A snapshot of the global therapeutic scenario for Neuroinflammation. 
  •  A review of the Neuroinflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  •  Coverage of products based on various stages of development ranging from discovery till registration stages. 
  •  A feature on pipeline projects on the basis of monotherapy and combined therapeutics. 
  •  Coverage of the Neuroinflammation pipeline on the basis of route of administration and molecule type. 
  •  Key discontinued pipeline projects. 
  •  Latest news and deals relating to the products. 

 Reasons to buy 

  •  Identify and understand important and diverse types of therapeutics under development for Neuroinflammation. 
  •  Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  •  Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. 
  •  Devise corrective measures for pipeline projects by understanding Neuroinflammation pipeline depth and focus of Indication therapeutics. 
  •  Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. 
  •  Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. 

 Additional Information 

 Companies Mentioned 

  •  Baxter International Inc. 
  •  Affectis Pharmaceuticals AG 
  •  to-BBB technologies BV 

 Country 

 Global 

 Introduction 

 Global Markets Direct Report Coverage 

 Neuroinflammation Overview 

 Therapeutics Development 

 An Overview of Pipeline Products for Neuroinflammation 

 Neuroinflammation Therapeutics under Development by Companies 

 Neuroinflammation Therapeutics under Investigation by Universities/Institutes 

 Discovery and Pre-Clinical Stage Products 

 Comparative Analysis 

 Neuroinflammation Therapeutics - Products under Development by Companies 

 Neuroinflammation Therapeutics - Products under Investigation by Universities/Institutes 

 Companies Involved in Neuroinflammation Therapeutics Development 

 Baxter International Inc. 

 Affectis Pharmaceuticals AG 

 to-BBB technologies BV 

 Neuroinflammation - Therapeutics Assessment 

 Assessment by Monotherapy Products 

 Assessment by Route of Administration 

 Assessment by Molecule Type 

 Drug Profiles 

 immune globulin intravenous (human) - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 AFC-5261 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 diazoxide - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 pegylated liposomal methylprednisolone - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 NT-KO-009 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 NT-KO-012 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 NT-CC-017 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 VCE-003 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 VCE-004 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 Antibody For Inflammation - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 lovastatin - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 VCE-006 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 artemisinin - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 Drug For Neuroinflammation - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 5-Methylthiazole Analogs - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 FP7 Project - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 Neuroinflammation Therapeutics - Drug Profile Updates 

 Neuroinflammation Therapeutics - Dormant Products 

 Appendix 

 Methodology 

 Coverage 

 Secondary Research 

 Primary Research 

 Expert Panel Validation 

 Contact Us 

 Disclaimer 

 List of Tables 

 Number of Products Under Development for Neuroinflammation, H2 2013 

 Products under Development for Neuroinflammation - Comparative Analysis, H2 2013 

 Number of Products under Development by Companies, H2 2013 

 Number of Products under Investigation by Universities/Institutes, H2 2013 

 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 

 Products under Development by Companies, H2 2013 

 Products under Investigation by Universities/Institutes, H2 2013 

 Baxter International Inc., H2 2013 

 Affectis Pharmaceuticals AG, H2 2013 

 to-BBB technologies BV, H2 2013 

 Assessment by Monotherapy Products, H2 2013 

 Assessment by Stage and Route of Administration, H2 2013 

 Assessment by Stage and Molecule Type, H2 2013 

 Neuroinflammation Therapeutics - Drug Profile Updates 

 Neuroinflammation Therapeutics - Dormant Products 

 List of Figures 

 Number of Products under Development for Neuroinflammation, H2 2013 

 Products under Development for Neuroinflammation - Comparative Analysis, H2 2013 

 Products under Development by Companies, H2 2013 

 Products under Investigation by Universities/Institutes, H2 2013 

 Discovery and Pre-Clinical Stage Products, H2 2013 

 Assessment by Monotherapy Products, H2 2013 

 Assessment by Route of Administration, H2 2013 

 Assessment by Stage and Route of Administration, H2 2013 

 Assessment by Molecule Type, H2 2013 

 Assessment by Stage and Molecule Type, H2 2013